RxDoctor Payments Data

Christine Thurston, DO

Internal Medicine · Mandeville, LANPI 1700173556

Payments from drug & device makers

$3,152in general payments, 2019–2025

Across 52 payments — averaging $60.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$790
  • AstraZeneca$616
  • Exact Sciences$373
  • Lilly USA, LLC$332
  • Dexcom, Inc.$325
  • Abbott$288
  • plus $428 from 3 others

What the payments were for

  • Food & beverage$3,140100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,152 in reported general payments places this provider in the 80th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$37,978
Medicare patients
139
Services billed
644

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide95$90,432
MounjaroTirzepatide59$63,542
WegovySemaglutide28$36,807
JardianceEmpagliflozin12$14,430
Breo ElliptaFluticasone/Vilanterol22$8,292
XareltoRivaroxaban12$6,490
Rosuvastatin Calcium117$2,044
Levothyroxine Sodium171$1,648
Atorvastatin Calcium222$1,609
Pantoprazole Sodium105$1,017
Ezetimibe41$919
Albuterol Sulfate HfaAlbuterol Sulfate33$897
Fluticasone Propionate50$846
Amlodipine Besylate144$825
SynthroidLevothyroxine Sodium22$801

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$790$127,240123 claims
Lilly USA, LLCMounjaro$332$63,54259 claims
AbbVieSynthroid$198$80122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Mandeville

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →